European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 06, Issue 01, 2019

Original Case Study

TARGETING LYSOSOMAL DYSFUNCTION IN WOLMAN DISEASE

Dr. K. Atchuta Kumar[1*]

1*Professor, Bhaskara Institute of Pharmacy, Komatipalli, Bobbili, Andhra pradesh

***Corresponding Author:** E-mail: dratchut99@gmail.com

*Professor, Bhaskara Institute of Pharmacy, Komatipalli, Bobbili, Andhra pradesh

ABSTRACT:

Wolman disease is a rare lysosomal storage disorder caused by mutations in the LIPA gene, resulting in deficient lysosomal acid lipase (LAL) enzyme activity. This deficiency leads to the accumulation of cholesterol esters and triglycerides, causing severe systemic manifestations and a shortened lifespan. This article aims to provide an overview of Wolman disease. Additionally, it explores the potential of pharmacological interventions to target lysosomal dysfunction, reduce lipid accumulation, and ameliorate the clinical manifestations of Wolman disease.

Keywords: Wolman disease, lysosomal storage disorder, LIPA gene, lysosomal acid lipase deficiency, cholesterol esters, triglycerides, lysosomal function, ameliorate.

INTRODUCTION:

Wolman disease is an autosomal recessive disorder caused by mutations in the lysosomal acid lipase (LIPA) gene, resulting in the deficiency or complete absence of functional lysosomal acid lipase enzyme activity. This leads to impaired breakdown of cholesterol esters and triglycerides within lysosomes, resulting in their accumulation in various tissues. The excessive accumulation of cholesterol and triglycerides in tissues such as the liver, spleen, and adrenal glands leads to hepatosplenomegaly, adrenal calcifications, and adrenal insufficiency. Currently, the management of Wolman disease primarily focuses on supportive care, including nutritional support, enzyme replacement therapy, and management of complications such as adrenal insufficiency. The limitations and challenges associated with these treatment approaches are discussed, highlighting the need for alternative therapeutic strategies.[1] The hepatosplenomegaly observed in Wolman disease is a consequence of lipid-laden macrophages infiltrating the liver and spleen. These macrophages, also known as foam cells, accumulate excessive cholesterol esters and triglycerides due to the impaired lysosomal breakdown. The accumulation of lipids in these organs can lead to hepatocellular dysfunction, fibrosis, and eventually liver failure. Adrenal calcifications are another hallmark feature of Wolman disease. The adrenal glands play a crucial role in producing hormones, including cortisol and aldosterone. In Wolman disease, the accumulation of lipids within the adrenal glands leads to calcification and destruction of the adrenal tissue, resulting in adrenal insufficiency. Adrenal insufficiency can manifest as fatigue, weight loss, low blood pressure, electrolyte imbalances, and potentially life-threatening adrenal crises.[2] The underlying genetic cause of Wolman disease is mutations in the LIPA gene, which encodes the lysosomal acid lipase enzyme. These mutations can result in a complete absence or significantly reduced activity of the enzyme. The inheritance pattern of Wolman disease is autosomal recessive, meaning that affected individuals inherit two copies of the mutated LIPA gene, one from each parent. Currently, there is no cure for Wolman disease, and treatment primarily focuses on managing symptoms and complications. Enzyme replacement therapy (ERT) with recombinant lysosomal acid lipase has shown some promise in reducing lipid accumulation and improving certain clinical manifestations. However, ERT has limitations, including the inability to effectively cross the blood-brain barrier, limiting its impact on neurological

symptoms.[3] Emerging therapeutic strategies for Wolman disease include the use of small molecule chaperones to enhance the activity of residual lysosomal acid lipase, gene therapy to introduce functional copies of the LIPA gene, and other innovative approaches targeting lysosomal function and lipid metabolism.[4]

LAL DEFICIENCY

LAL helps keep the level of cholesterol in cells constant. Wolman disease is caused by a complete lack of LAL activity, whereas cholesteryl ester storage disease (CESD) is the attenuated phenotype of a partial deficiency, in which some residual enzyme activity is retained. One important aspect of the illness phenotype is residual LAL activity.[5] The clinical trajectory of the illness is likely also influenced by additional epigenetic variables.[6]

ETIOLOGY

Triglycerides (TGs) and cholesteryl esters (CEs), which are brought to the lysosomes by receptor-mediated endocytosis, are hydrolyzed by lysosomal acid lipase (LAL). Two different phenotypes, Wolman disease (WD) and cholesteryl ester storage disease (CESD), are caused by mutations in the human LAL (hLAL) gene.[7] The incidence of WD, an infantile-onset condition, is less than 1/300,000 live births. Infants with WD who are affected show extensive collections of CEs and TGs in macrophages located throughout the viscera. Liver and lung TG and CE accumulations can cause pulmonary fibrosis and liver cirrhosis.[8] Calcification and insufficiency of the adrenal gland are caused by an excess of CEs in the zona reticularis. Patients with WD have cachexia as a result of malabsorption brought on by an accumulation of engorged macrophages in the small intestine's villi. Patients with WD typically live for six months. On the other hand, CESD is more common than WD and has a later onset. The frequency is not known, however it could be two or three times higher than WD. The increase of macrophages (Kupffer cells) engorged with CEs leads largely to hepatomegaly, which may be the only clinical indication of CESD. Because of the compromised homeostasis of cholesterol, CE, and TG, some patients experience early atherosclerosis, cirrhosis, and/or cholestasis. Due to the patient's cachexia and the requirement for matched donors, bone marrow transplantation has had only a limited therapeutic impact in the treatment of WD. Perhaps more promising is the use of unrelated umbilical cord blood transplantation to treat WD.[9] I.e. In order to treat CESD, HMG-CoA-reductase inhibitors have been utilized to reduce the amount of CEs that accumulate in the liver and spleen. Although these medicines don't consistently appear to have any phenotypic or outcome impacts, certain effects on lipoprotein metabolism have been noted. One CESD patient experienced improved results in lowering plasma LDL-cholesterol after receiving a combination medication of lovastatin and ezetimibe, an inhibitor of the Niemann-Pick type C1-like gene product that controls sterol absorption in the small intestine.[10]

CLINICAL CHARACTERISTICS

A rare genetic condition affecting lipid metabolism is called Wolman disease. It is distinguished by the subsequent clinical characteristics:

- Infantile Onset: Usually within the first few weeks or months of life, symptoms start to show.[11]
- Failure to Thrive: Infants with Wolman disease struggle to gain weight and develop normally.[12]
- Enlarged Liver and Spleen: Patients with the disease frequently have splenomegaly (enlarged spleen) and hepatomegaly (enlarged liver).[13]
- Malabsorption: Wolman disease causes issues with the body's ability to absorb nutrients, which can lead to malnutrition and persistent diarrhea.[14]
- Adrenal Calcification: Adrenal insufficiency can result from calcification of the adrenal glands.[15]
- Low Muscle Tone: Infants affected by this condition may have weak muscle tone, which may hinder their development of motor skills and ability to move.

- Progressive Neurological Symptoms: Wolman disease patients may experience progressive neurological symptoms over time, such as intellectual disability and developmental delays.[16]
- Cherry Red Spot: A recognizable cherry-red spot in the retina of the eye may be discovered during an ophthalmic examination.
- Steatorrhea: Malabsorption-related fatty stools.
- Severe Atherosclerosis: Even in very young children, Wolman disease can result in severe atherosclerosis, or hardening of the arteries, which raises the risk of cardiovascular problems.[17]

BASIC LABORATORY TEST

Lipid buildup in multiple tissues is caused by a lack of lysosomal acid lipase (LAL) enzyme activity, which is a rare genetic disorder known as Wolman disease. It is possible to diagnose Wolman disease with certain laboratory tests. Often, these examinations consist of:

- Lysosomal Acid Lipase (LAL) Enzyme Activity Assay :The main diagnostic procedure for Wolman disease is the Lysosomal Acid Lipase (LAL) Enzyme Activity Assay. It gauges the LAL enzyme's activity in other tissues, such as blood. Wolman disease patients will either have very low or no LAL enzyme activity.[18]
- Lipid Analysis: To determine the amounts of particular lipids, especially cholesterol esters and triglycerides, which build up in tissues as a result of the enzyme deficiency, lipid profiles may be analyzed.
- Genetic Testing: The genetic foundation of the illness is confirmed by the detection of mutations in the LIPA gene by molecular genetic testing. Particularly helpful applications for this include carrier screening and family therapy.[19]
- Liver Function Tests: Liver function tests may be carried out to evaluate the health of the liver because Wolman disease can result in hepatomegaly, or an enlarged liver, and liver dysfunction.
- Imaging Studies: The liver and spleen can be seen through imaging procedures like CT, MRI, or ultrasound to determine their size and health.
- Bone Marrow Examination: A bone marrow biopsy may be necessary in certain circumstances to determine whether lipid-laden macrophages, which may be a defining characteristic of the illness, are present.
- Additional Tests: Other tests, such as liver function tests, may be ordered to evaluate organ function and rule out other conditions that may present with similar symptoms, depending on the patient's particular symptoms and clinical presentation.[20]

It is noteworthy that a combination of these tests, including clinical symptom assessment and genetic testing to confirm the presence of LIPA gene mutations, are frequently used to reach a definitive diagnosis of Wolman disease. For a thorough assessment and diagnosis, a geneticist or a specialist in metabolic disorders should be consulted if Wolman disease is suspected. For affected people to receive the right care and support, an early diagnosis is essential. Following a confirmed diagnosis of Wolman disease, the medical staff can offer suitable care and assistance. Wolman disease is a severe condition that frequently results in significant health complications for affected individuals, so early diagnosis is essential. In order to manage the condition within the family, a diagnosis enables genetic counseling and family planning.[21]

THERAUPEUTIC MANAGEMENT

A severe and progressive genetic disorder called Wolman disease is brought on by a lack of lysosomal acid lipase (LAL) enzyme activity. Regretfully, Wolman disease does not currently have a treatment. The main goals of Wolman disease treatment are symptom relief, supportive care, and handling any complications that may arise from the illness. The following are some essential elements of Wolman disease therapeutic management:

- Supportive and Symptomatic Therapy: Healthcare providers strive to treat the different Wolman disease symptoms. This could entail taking care of digestive problems, offering dietary assistance, and controlling pain and discomfort.[22]
- Nutritional Support: Children with Wolman disease frequently need specialized nutritional support because of malabsorption and difficulty gaining weight. To make sure they get the nutrients they need, enteral or parenteral nutrition may be used.
- Heptatomegaly and Splenomegaly Management: Regular monitoring is the best way to manage hepatomegaly (enlarged liver) and splenomegaly (enlarged spleen), though treatment or interventions might be required in some circumstances.
- Management of Adrenal Insufficiency: An adrenal insufficiency may occur in some Wolman disease patients. Hormone replacement treatment might be necessary in these situations to treat the illness.[23]
- Pain Management: Appropriate painkillers or other interventions can help manage the pain and discomfort brought on by Wolman disease.
- Cardiovascular Surveillance: Severe atherosclerosis, which raises the risk of cardiovascular problems, can result from Wolman disease. To address these complications, routine cardiovascular monitoring and interventions might be required.
- Genetic Counseling: Families who have a member with Wolman disease may find it helpful to learn about the condition's genetic foundation and the possibility of passing it on to subsequent generations.[24]
- Clinical Trials and Research: Potential therapies for Wolman disease are being actively investigated by researchers. Some patients may be able to access experimental therapies by taking part in clinical trials.[25]

It's crucial to remember that Wolman disease management is complicated, and treatment should be given by a group of medical specialists with backgrounds in pediatrics, genetics, and metabolic disorders. Enhancing the afflicted person's quality of life and managing the disease's complications are the two main objectives of therapy. In order to provide the best care possible, a multidisciplinary approach is frequently necessary due to the rarity and severity of Wolman disease.[26]

PROPHYLAXIS

Lysosomal acid lipase (LAL) enzyme activity deficit is the cause of the rare and severe genetic disorder known as Wolman disease. Here, prophylaxis refers to managing the risk of the disease in future generations through genetic counseling and other preventive measures, as opposed to treating the disease in afflicted individuals. The following are some essential elements of Wolman disease prophylaxis:

- Genetic Guidance: The keystone of Wolman disease prevention is genetic counseling. Individuals who possess LIPA gene mutations (heterozygous carriers) ought to obtain genetic counseling in order to ascertain the likelihood of transmitting the illness to their progeny. Carrier screening can help find people who might pass on the disease to their offspring.[27]
- Infant Examination: Prenatal testing, such as chorionic villus sampling (CVS) or amniocentesis, can be offered to families with a history of Wolman disease or known carrier status in order to ascertain whether an unborn child has the disease. This enables parents to decide on a pregnancy with knowledge.[28]
- Genetic Diagnosis Preimplantation (PGD): PGD might be an option if one or both parents are known carriers. In order to choose embryos that are devoid of LIPA gene mutations prior to implantation, this entails in vitro fertilization (IVF) and genetic testing of the embryos.[29]
- Preparing the Family: With the help of genetic testing and counseling, families who are at risk for Wolman disease can make well-informed decisions regarding family planning. To have children

without the risk of the disease, they can think about surrogacy, donor gametes, adoption, or other options.[30]

- Educational Resources: It is crucial for families to make well-informed decisions about Wolman disease, its inheritance patterns, and the various genetic testing options that are available.[31]

It is crucial to speak with a genetic counselor or a medical professional who specializes in metabolic disorders and genetics about the particular risk factors and ways to control the likelihood of Wolman disease in your family. The goal of Wolman disease prevention is to stop the birth of afflicted people by using genetic testing and educated family planning.[32]

DISCUSSION

Addressing the disruption of lysosomes in Wolman disease presents a formidable challenge. Researchers are exploring novel tactics, including Enzyme Replacement Therapy (ERT), which endeavors to reintroduce the deficient enzyme LIPA, though its utility in Wolman's extreme cases remains limited. Gene Therapy, a cutting-edge approach, seeks to replace the faulty LIPA gene with a functional one, offering potential enduring benefits. Small Molecule Therapies are under scrutiny, designed to enhance lysosomal function and curtail lipid accumulation, potentially ameliorating symptoms and disease progression. Substrate Reduction Therapy (SRT) targets the reduction of accumulating lipids and can complement other treatments. Chaperone Therapy, another innovative avenue, employs stabilizing molecules to enhance the function of faulty enzymes. Stem Cell Transplantation, such as hematopoietic stem cell transplantation, has been explored to introduce functional LIPA-producing cells. Given the severity of Wolman disease, these approaches signify the frontier of medical research, demanding a multidisciplinary collaboration spanning genetics, molecular biology, and clinical trials, underscoring the paramount importance of patients and families partaking in these endeavors to broaden our understanding and treatment horizons.[1,14,32]

CONCLUSION

Lysosomal dysfunction and lipid accumulation are hallmarks of the debilitating rare genetic disorder known as Wolman disease. The underlying pathophysiology is not addressed by the current treatment approaches, despite the fact that they relieve symptoms. Investigating pharmacological therapies that target lysosomal dysfunction and lower lipid accumulation has encouraging potential to enhance Wolman disease patients' quality of life and prognosis. Wolman Disease is a rare lysosomal storage disorder characterized by the accumulation of cholesterol and triglycerides. Selenipase alfa has been recommended in a few reports as a medication to treat the illness. Nevertheless, Wolman's disease lacks a specific treatment or cure. Exploring pharmacological interventions to enhance lysosomal function or reduce lipid accumulation.

REFERENCE:

1. Aguisanda F, Thorne N, Zheng W. Targeting Wolman disease and cholesteryl ester storage disease: disease pathogenesis and therapeutic development. Current chemical genomics and translational medicine. 2017;11:1.
2. Tylki-Szymanska A. Lysosomal acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. Current Medical Literature. 2012;10(1):1.
3. Du H, Cameron TL, Garger SJ, Pogue GP, Hamm LA, White E, Hanley KM, Grabowski GA. Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. Journal of lipid research. 2008 Aug 1;49(8):1646-57.
4. Wraith JE. Lysosomal disorders. InSeminars in neonatology 2002 Feb 1 (Vol. 7, No. 1, pp. 75-83). WB Saunders.
5. Hoffman EP, Barr ML, Giovanni MA, Murray MF. Lysosomal acid lipase deficiency.

6. Tylki-Szymańska A, Jurecka A. Lysosomal acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2014 Jan 1;35(1):99-106.
7. Anderson RA, Byrum RS, Coates PM, Sando GN. Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease. Proceedings of the National Academy of Sciences. 1994 Mar 29;91(7):2718-22.
8. Menon J, Shanmugam N, Srinivas S, Vij M, Jalan A, Srinivas Reddy M, Rela M. Wolman's Disease: A Rare Cause of Infantile Cholestasis and Cirrhosis. Journal of Pediatric Genetics. 2020 Aug 20;11(02):132-4.
9. Hannah WB, Ryan K, Pendyal S, Burrow TA, Harley SE, Cordell M, McCall CM, Mavis AM, Tan QK, Kishnani PS. Clinical insights from Wolman disease: Evaluating infantile hepatosplenomegaly. American Journal of Medical Genetics Part A. 2022 Nov;188(11):3364-8.
10. Fasano T, Pisciotta L, Bocchi L, Guardamagna O, Assandro P, Rabacchi C, Zanoni P, Filocamo M, Bertolini S, Calandra S. Lysosomal lipase deficiency: molecular characterization of eleven patients with Wolman or cholesteryl ester storage disease. Molecular genetics and metabolism. 2012 Mar 1;105(3):450-6.
11. Guazzi GC, Martin JJ, Philippart M, Roels H, Van der Eecken H, Vrints L, Delbeke MJ, Hooft C. Wolman's disease. European neurology. 1968;1(6):334-62.
12. Röyttä M, Fagerlund AS, Toikkanen S, Salmi TT, Jorde LB, Forsius HR, Eriksson AW. Wolman disease: morphological, clinical and genetic studies on the first Scandinavian cases. Clinical genetics. 1992 Jul;42(1):1-7.
13. Hannah WB, Ryan K, Pendyal S, Burrow TA, Harley SE, Cordell M, McCall CM, Mavis AM, Tan QK, Kishnani PS. Clinical insights from Wolman disease: Evaluating infantile hepatosplenomegaly. American Journal of Medical Genetics Part A. 2022 Nov;188(11):3364-8.
14. Taurisano R, Maiorana A, De Benedetti F, Dionisi-Vici C, Boldrini R, Deodato F. Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation. European journal of pediatrics. 2014 Oct;173:1391-4.
15. Zhang J, Chen QL, Guo S, Li YH, Li C, Zheng RJ, Luo XQ, Ma HM. Clinical characteristics of sitosterolemic children with xanthomas as the first manifestation. Lipids in Health and Disease. 2022 Dec;21(1):1-0.
16. Foladi N, Aien MT. CT features of Wolman disease (lysosomal acid lipase enzyme deficiency)–A case report. Radiology Case Reports. 2021 Oct 1;16(10):2857-61.
17. Eto Y, Kitagawa T. Wolman's disease with hypolipoproteinemia and acanthocytosis: Clinical and biochemical observations. The Journal of pediatrics. 1970 Nov 1;77(5):862-7.
18. Stein J, Zion Garty B, Dror Y, Fenig E, Zeigler M, Yaniv I. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. European journal of pediatrics. 2007 Jul;166:663-6.
19. Marshall WC, Ockenden BG, Fosbrooke AS, Cumings JN. Wolman's disease. A rare lipidosis with adrenal calcification. Archives of disease in childhood. 1969 Jun;44(235):331.
20. Boldrini R, Devito R, Biselli R, Filocamo M, Bosman C. Wolman disease and cholesteryl ester storage disease diagnosed by histological and ultrastructural examination of intestinal and liver biopsy. Pathology-Research and Practice. 2004 May 17;200(3):231-40.
21. Krivit W, Peters C, Dusenbery K, Ben-Yoseph Y, Ramsay NK, Wagner JE, Anderson R. Wolman disease successfully treated by bone marrow transplantation. Bone marrow transplantation. 2000 Sep;26(5):567-70.
22. Potter JE, Petts G, Ghosh A, White FJ, Kinsella JL, Hughes S, Roberts J, Hodgkinson A, Brammeier K, Church H, Merrigan C. Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease. Orphanet Journal of Rare Diseases. 2021 May 21;16(1):235.

23. Demaret T, Lacaille F, Wicker C, Arnoux JB, Bouchereau J, Belloche C, Gitiaux C, Grevent D, Broissand C, Adjaoud D, Abi Warde MT. Sebelipase alfa enzyme replacement therapy in Wolman disease: a nationwide cohort with up to ten years of follow-up. Orphanet Journal of Rare Diseases. 2021 Dec;16(1):1-9.
24. Baronio F, Conti F, Miniaci A, Carfagnini F, Di Natale V, Di Donato G, Testi M, Totaro C, De Fanti A, Boenzi S, Dionisi-Vici C. Diagnosis, treatment, and follow-up of a case of Wolman disease with hemophagocytic lymphohistiocytosis. Molecular Genetics and Metabolism Reports. 2022 Mar 1;30:100833.
25. Cossette A, Castilloux J, Bouffard C, Laflamme J, Faure C, Benlamlih S, Abel F, Beecroft M, Francis M, Drouin R. Early diagnosis and successful long-term management of a rare, severe lysosomal acid lipase deficiency/Wolman disease patient: Infancy to age five. Canadian Liver Journal. 2022 Aug 1;5(3):428-34.
26. Aguisanda F, Yeh CD, Chen CZ, Li R, Beers J, Zou J, Thorne N, Zheng W. Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics. Orphanet Journal of Rare Diseases. 2017 Dec;12(1):1-3.
27. Gramatges MM, Dvorak CC, Regula DP, Enns GM, Weinberg K, Agarwal R. Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Bone marrow transplantation. 2009 Oct;44(7):449-50.
28. Yanir A, Allatif MA, Weintraub M, Stepensky P. Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complications. Molecular Genetics and Metabolism. 2013 Jun 1;109(2):224-6.
29. Jayakumar I, Gude A, Renangi M, Valliyappan S, Swaminathan VV, Meena S, Varla H, Chandar R, Uppuluri R, Raj R. Successful matched unrelated donor hematopoietic stem cell transplantation for infantile Wolman disease. Pediatric Hematology Oncology Journal. 2023 Mar 1;8(1):1-3.
30. Balado AC, de Castro López MJ, Pintos PS, Vilar EB, Montero JG, Quintanilla LG, Pico MC, Ferro IZ. 4CPS-031 Efficacy and safety of high-dose twice-weekly sebelipase alfa in severe-onset Wolman disease: a case report.
31. Pichler H, Horner K, Engstler G, Poetschger U, Glogova E, Karlhuber S, Martin M, Eibler W, Witt V, Holter W, Matthes-Martin S. Cost-effectiveness of defibrotide in the prophylaxis of veno-occlusive disease after pediatric allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2017 Jul 1;23(7):1128-33.
32. STOKES J, WOLMAN IJ, CARPENTER HC, Margolis J. PROPHYLACTIC USE OF PARENTS'WHOLE BLOOD IN ANTERIOR POLIOMYELITIS: PHILADELPHIA EPIDEMIC OF 1932. American Journal of Diseases of Children. 1935 Sep 1;50(3):581-95.